Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Absenger, G; Terzic, J; Bezan, A.
ASCO update: lung cancer.
Memo. 2017; 10(4):224-227 Doi: 10.1007/s12254-017-0373-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Absenger Gudrun

Spiegelberg Jasmin Alija

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

In the past few years there have been major changes in the treatment landscape in oncology; lung cancer is affected by those changes like almost no other solid tumor. The rise of further second- and third-line tyrosine kinase inhibitors offers sequential therapy for patients with mutated non-small-cell lung cancer. Immunotherapy has found its way into clinical routine and presents us with new challenges in managing side effects, evaluating treatment response and deciding on how long we treat our patients. The treatment algorithm of lung cancer has changed in the last month and further practice-changing trials are coming up, so treating lung cancer patients shows nowadays a more challenging perspective with the possibility of subsequently applied individual therapies. This article provides a brief overview of the highlights presented at the ASCO (American Society of Clinical Oncology) annual meeting this year in Chicago.

Find related publications in this database (Keywords)

Carcinoma

non-small-cell lung

Carcinoma

small-cell lung

Lung neoplasms

Immunotherapy

Treatment algorithms

© Med Uni Graz • Impressum